Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years. Merck received accelerated approval for Keytruda from the Food and Drug Administration in September 2014 to treat advanced or unresectable melanoma. The drug has since been approved to treat more than 15 types of cancers and has been a key contributor to Merck's revenu ...

Merck & Co (NYSE:MRK) M&A announcement March 25, 2026 08:00 AM ET Company ParticipantsCaroline Litchfield - CFODean Li - President of Merck Research LaboratoriesEvan Seigerman - Managing Director and Head of Healthcare ResearchJannie Oosthuizen - EVP and President of Oncology and MSD InternationalJason Gerberry - Managing Director of Equity ResearchLuisa Hector - Head of Global Pharma Equity Research and Co-Head of the Global Pharmaceuticals TeamMarjorie Green - SVP and Head of Oncology, Global Clinical Dev ...

Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia. ...

Pharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion, the company said Wednesday.This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028. Terns shares rose 5.3% while Merck stock was largely flat in premarket trading. This is breaking news. Please refresh for updates. ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 20, 2026, Citi raised the price target on Merck & Co., Inc. (NYSE:MRK) to $125 from $120 and maintained a Neutral rating. On March 18, 2026, Merck’s Animal Health division announced that the FDA approved an expanded label for Bravecto Quantum in dogs, adding treatment and control for additional tick species for up to 12 months with a single injection. The product, first approved in July 2025, remains availab ...

默克公司将以约67亿美元的股权价值收购TERNS公司，每股53美元。 ...

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv March 25 (Reuters) - Merck (MRK.N), opens new tabsaid on Wednesday it would buy biotech Terns Pharma (TERN.O), opens new tabin a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss for its blockbuster therapy Keytruda. Sign up here. Reporting by ...

The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection. ...

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have entered into a ...

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights, opens new tab Reporting by Fabiola Arámburo in Mexico City; Editing by Sherry Jacob-Phillips Our Standards: The Thomson Reuters Trust Principles., opens ...